OVID - Ovid's soticlestat shows positive effect in rare epilepsies

Ovid Therapeutics (OVID) reported results from Phase 2 ARCADE and ENDYMION studies evaluating soticlestat (OV935/TAK-935) in patients with CDKL5 deficiency disorder ((CDD)) and Dup15q syndrome (Dup15q), two rare developmental and epileptic encephalopathies. Data from both the studies showed seizure frequency reduction over time, and soticlestat was well tolerated.In 12 CDD patients, median reductions of 24% in motor seizures was observed, during the 12-week maintenance period. This increased to 50% reduction in the ENDYMION study in the five CDD patients, who reached nine months of continuous treatment.In 8 Dup15q patients, an increase in median motor seizure frequency in the ARCADE study was observed; however, longer-term data from the four Dup15q patients with nine months of treatment experienced a 74% reduction in median motor seizure frequency.This final results are in line with the preliminary data announced earlier this year.Last month, the company announced positive data from Phase 2 ELEKTRA trial, demonstrating a statistically significant 27.8% median reduction from baseline in convulsive seizure and drop seizure

For further details see:

Ovid's soticlestat shows positive effect in rare epilepsies